Australian regulators issue warning on Novartis' Lamisil

Share this article:
Australia's drug and medical device regulatory agency, the Therapeutic Goods Administration (TGA), has issued a warning concerning nail fungus treatment Lamisil (terbinafine) tablets following reports of three deaths and severe liver reactions among patients. 
The TGA's Adverse Drug Reactions Advisory Committee (ADRAC) received 722 adverse event reports related to Lamisil, including 70 liver reactions, 61 implicating the tablet form as the sole suspected drug.
The committee warned prescribers that the oral formulation of Lamisil should only be prescribed short-term and as a last resort.
“Oral terbinafine should be prescribed only after topical therapy has failed and for the shortest time possible, in accordance with the current product information,” the committee wrote in its drug reactions bulletin.
A spokesman for Novartis said in published reports that serious and life-threatening liver reactions were rare and well-documented side effects of oral anti-fungal medications. The company said it agreed with the advice issued by the ADRAC.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.